U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151118) titled 'ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer' on Aug. 20.
Brief Summary: This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea. Tissue-based genomic profiling is often limited due to the anatomical challenges of tumor biopsy and insufficient DNA quality. ctDNA analysis offers a minimally invasive alternative for identifying actionable genetic alterations, including Fibroblast Growth Factor Receptor 2 (FGFR2) fusions, Isocitrate Dehydrogenase 1 (IDH1) mutations, and Human ...